Herranz Lab Select Publications

  1. Fabbri, G., Holmes, A., Viganotti, M., Scuoppo, C., Belver, L., Herranz, D., Yan, XJ., Kieso, Y., Rossi, D., Gaidano, G., Chiorazzi, N., Ferrando, AA., and Dalla-Favera, R. (2017) Common non-mutational NOTCH1 activation in Chronic Lymphocytic Leukemia. Proc Natl Acad Sci USA, In press. (PMID: 28314854)
     
  2. Sánchez-Martín, M., Ambesi-Impiombato, A., Quin, Y., Herranz, D., Bansal, M., Girardi, T., Paietta, E., Tallman, MS., Rowe, JM., De Keersmaecker, K., Califano, A., and Ferrando AA. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci USA, 114, 2006-2011. (PMID: 28174276)
     
  3. Herranz, D., Ambesi-Impiombato, A., Sudderth, J., Sánchez-Martín, M., Belver, L., Tosello, V., Xu, L., Wendorff, AA., Castillo, M., Haydu, JE., Márquez, J., Matés, JM., Kung, AW., Rayport, S., Cordon-Cardo, C., DeBerardinis RJ. and Ferrando, AA. (2015). Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in acute lymphoblastic leukemia. Nat Med, 21: 1182-1189. (PMID: 26390244)
    Preview comment in Cell metabolism (2015), 22: 759-760. (PMID: 26536486)
    Research Watch comment in Cancer Discovery (2015), 11: 1123. (PMID: 26428986)
     
  4. Herranz, D., Ambesi-Impiombato, A., Palomero, T., Schnell, SA., Belver, L., Wendorff, AA., Xu, L., Castillo-Martin, M., Llobet-Navás, D., Cordon-Cardo, C., Clappier, E., Soulier, J., and Ferrando, AA. (2014). A NOTCH1-driven MYC enhancer promotes T-cell development, transformation and acute lymphoblastic leukemia. Nat Med, 20: 1130-1137. (PMID: 25194570)
    News&Views comment in Nature Medicine (2014), 20: 1096-1097. (PMID: 25295936)
    Research Watch comment in Cancer Discovery (2014), 11: OF17. (PMID: 25367958)
     
  5. Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villaroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., Dieguez, C., Lopez, M., Frühbeck, G., and Nogueiras, R. (2014). GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes, 63: 3346-3358. (PMID: 24917578)
     
  6. Piovan, E., Yu, J., Tosello, V., Herranz, D., Ambesi-Impiombato, A., Da Silva, AC., Sánchez-Martín, M., Pérez-García, A., Rigo, Castillo, M., Indracolo, S., Cross, JR., de Stanchina, E., Paietta,       E., Racevskis, J., Rowe, JM., Tallman, MS., Basso, G., Meijerink, JP., Cordon-Cardo, C., Califano, A., and Ferrando, AA. (2013). Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell, 29, 766-776. (PMID: 24291004)
     
  7. García-Rodríguez, J., Barbier-Torres, L., Fernández-Álvarez, S., Gutiérrez-de Juan, V., Monte, MJ., Halilbasic, E., Herranz, D., Alvarez, L., Aspichueta, P., Marin, JJG., Trauner, M., Mato, JM., Serrano, M., Beraza, N., and Martínez-Chantar, ML. (2014). Sirt1 controls liver regeneration by regulating BA metabolism through FXR and mTOR signaling. Hepatology, 59, 1972-1983. (PMID: 24338587)
     
  8. Wauters, E., Sanchez-Arevalo Lobo, VJ., Pinho, AV., Mawson, A., Herranz, D., Wu, J.,   Cowley, MJ., Colvin, EK., Ngawi Njicop, E., Sutherland, RL., Liu, T., Serrano, M., Bouwens, L., Real, FX., Biankin, AV., and Rooman, I. (2013). Sirtuin-1 regulates acinar to ductal metaplasia and supports cancer cell viability in pancreatic cancer. Cancer Res, 73, 2357-2367. (PMID: 23370328)
     
  9. Herranz, D., Maraver, A., Cañamero, M., Gómez-López, G., Inglada-Pérez, L., Robledo, M., Castelbanco, E., Matias-Guiu, X., and Serrano, M. (2013). SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. Oncogene, 32, 4052-56. (PMID: 22986535)
     
  10. Maraver, A., Fernández-Marcos, PJ*., Herranz, D*., Muñoz-Martin, M., Gomez-Lopez, G., Cañamero, M., Mulero, F., Megías, D., Sanchez-Carbayo., M., Shen, J., Sanchez-Cespedes, M., Palomero, T., Ferrando, A., and Serrano, M. (2012). Therapeutic effect of g-secretase inhibition in KrasG12V-driven non- small cell lung carcinoma through derepression of DUSP1 phosphatase and inhibition of ERK. Cancer Cell, 22, 222-34. (PMID: 22897852) (*Equal contribution)
     
  11. Muñoz-Fontela, C., Gonzalez, D., Marcos-Villar, L., Campagna, M., Gallego, P., Gonzalez-Santamaria, J., Herranz, D., Gu, W., Serrano, M., Aaronson, SA., and Rivas, C. (2011). Acetylation is indeispensable for p53 antiviral ativity. Cell Cycle, 10, 3701-5. (PMID: 22033337)
     
  12. Herranz, D., Iglesias, G., Muñoz-Martin, M., and Serrano, M. (2011). Limited role of Sirt1 in cancer protection by dietary restriction. Cell Cycle, 10, 2215-17. (PMID: 21606675)
     
  13. Gambini, J., Gomez-Cabrera, MC., Borras, C., Valles, SL., Lopez-Grueso, R., Martinez-Bello, VE., Herranz, D., Pallardo, FV., Tresguerres, JA., Serrano, M., and Viña, J. (2011). Free [NADH]/[NAD+] regulates sirtuin expression. Arch Biochem Biophys, 512, 24-9. (PMID: 21575591)
     
  14. Campagna, M., Herranz D., Garcia, MA., Marcos-Villar, L., González- Santamaría, J., Gallego, P., Gutierrez, S., Collado, M., Serrano, M., Esteban, M., and Rivas C. (2011). SIRT1 stabilizes PML promoting its sumoylation. Cell Death Differ, 18, 72-9. (PMID: 20577263)
     
  15. Palacios, JA., Herranz, D., De Bonis, ML., Velasco, S., Serrano, M., Blasco MA. (2010). SIRT1 contributes to telomere maintenance in vivo and augments global homologous recombination.  J Cell Biol, 191, 1299-13. (PMID: 21187328)
     
  16. Calvanese, V., Lara, E., Suarez-Alvarez, B., Abu Dawud, R., Vazquez- Chantada, M., Martínez-Chantar, M., Embade, N., Horrillo, A., Hmadcha, A., Soria, B., Piazzolla, D., Herranz, D., Serrano, M., Mato, JM., Andrews, P., López-Larrea, C., Esteller, M., raga, MF. (2010). SIRT1 regulation of developmental genes during differentiation of stem cells. Proc Natl Acad Sci USA, 107, 13736-41. (PMID: 20631301)
     
  17. Herranz, D., Muñoz-Martin, M., Cañamero, M., Mulero, F., Martinez-Pastor, B., Fernandez-Capetillo, O., and Serrano, M. (2010). Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun, 1:3. (PMID: 20975665)
    Evaluated in the F1000 website
     
  18. Pfluger, P.T.*, Herranz D.*, Velasco-Miguel, S. *, Serrano, M. and Tschöp, M.H. (2008). Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA,105,9793-8. (PMID: 18599449) (*Equal contribution)
     
  19. Efeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L.T. and Serrano, M. (2007). Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res, 67, 7350-7357. (PMID: 17671205)
     
  20. Efeyan, A., Garcia-Cao, I., Herranz, D., Velasco-Miguel, V. and Serrano, M. (2006). Policing of oncogene activity by p53. Nature, 443, 159. (PMID: 16971940)

REVIEWS, PREVIEWS AND EDITORIALS

  1. Herranz, D. (2017). Glutaminolysis gets the spotlight in cancer. Oncotarget, 8, 10761-10762. (PMID: 28053289)
     
  2. Herranz, D., Ferrando AA. (2016). Targeting NOTCH1 in T-ALL: Starving the dragon. Cell Cycle, 15, 483-484. (PMID: 26864725)
     
  3. Herranz, D., Ferrando AA. (2015). An oncogenic enhancer enemy (N-Me) in T-ALL. Cell Cycle, 14, 167-168. (PMID: 25584678)
     
  4. Herranz, D., Serrano, M. (2010). Sirt1: recent lessons from mouse models. Nat Rev Cancer, 10, 819-823. (PMID: 21102633)
     
  5. Herranz, D., Serrano, M. (2010). Impact of Sirt1 on mammalian aging. Aging (Albany NY), 2, 315-316. (PMID: 20562473)

 

 

 

 

precision medicine at Rutgers Cancer Institute

 

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health